Do analysts prefer PMCB or ORGS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PMCB or ORGS more profitable?

Nuvilex has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Nuvilex's return on equity of 2.13% beat Orgenesis' return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 2.13% 1.69% Orgenesis -3,827.81% N/A -130.18%

Do analysts prefer ORGS or SYBX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ORGS or SYBX more profitable?

Synlogic has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Synlogic's return on equity. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% Synlogic N/A -26.47% -18.00%

Which has preferable valuation and earnings, ORGS or OBSV?

Orgenesis has higher revenue and earnings than ObsEva. Orgenesis is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orgenesis $662K 3.12 -$55.36M -$11.51 N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is ORGS or OBSV more profitable?

ObsEva has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% ObsEva N/A -416.36% -92.01%

Is ORGS or NKGN more profitable?

NKGen Biotech has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% NKGen Biotech N/A N/A -479.36%

Do analysts rate ATON or ORGS?

Portage Biotech currently has a consensus price target of $2.00, indicating a potential upside of 502.41%. Given Portage Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Portage Biotech is more favorable than Orgenesis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Portage Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ATON or ORGS more profitable?

Portage Biotech has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Portage Biotech N/A N/A N/A Orgenesis -3,827.81% N/A -130.18%

Orgenesis (ORGS) Competitors

$0.40 0.00 (0.00%)

As of 07/2/2026

Compare

ORGS vs. PMCB, SYBX, OBSV, NKGN, and ATON

Should you buy Orgenesis stock or one of its competitors? MarketBeat compares Orgenesis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Orgenesis include Nuvilex (PMCB), Synlogic (SYBX), ObsEva (OBSV), NKGen Biotech (NKGN), and Portage Biotech (ATON). These companies are all part of the "pharmaceutical products" industry.

How does Orgenesis compare to Nuvilex?

Nuvilex (NASDAQ:PMCB) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

In the previous week, Nuvilex's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
Nuvilex	Neutral
Orgenesis	Neutral

Nuvilex has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Nuvilex's return on equity of 2.13% beat Orgenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
Orgenesis	-3,827.81%	N/A	-130.18%

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 11.0% of Nuvilex shares are held by insiders. Comparatively, 1.9% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuvilex has higher earnings, but lower revenue than Orgenesis. Nuvilex is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A

Nuvilex has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.15, meaning that its stock price is 215% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Nuvilex beats Orgenesis on 8 of the 11 factors compared between the two stocks.

How does Orgenesis compare to Synlogic?

Orgenesis (NASDAQ:ORGS) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Synlogic has lower revenue, but higher earnings than Orgenesis. Synlogic is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A
Synlogic	$8K	1,024.95	-$23.36M	-$0.06	N/A

Orgenesis has a beta of 3.15, suggesting that its stock price is 215% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Synlogic'saverage media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
Synlogic	Neutral

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by insiders. Comparatively, 2.6% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Synlogic has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Synlogic	N/A	-26.47%	-18.00%

Summary

Synlogic beats Orgenesis on 8 of the 12 factors compared between the two stocks.

How does Orgenesis compare to ObsEva?

Orgenesis (NASDAQ:ORGS) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Orgenesis has higher revenue and earnings than ObsEva. Orgenesis is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

ObsEva has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
ObsEva	N/A	-416.36%	-92.01%

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 1.9% of Orgenesis shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Orgenesis has a beta of 3.15, indicating that its stock price is 215% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
ObsEva	Neutral

Summary

Orgenesis and ObsEva tied by winning 5 of the 10 factors compared between the two stocks.

How does Orgenesis compare to NKGen Biotech?

Orgenesis (NASDAQ:ORGS) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

In the previous week, NKGen Biotech had 2 more articles in the media than Orgenesis. MarketBeat recorded 2 mentions for NKGen Biotech and 0 mentions for Orgenesis. Orgenesis' average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
NKGen Biotech	Neutral

Orgenesis has a beta of 3.15, meaning that its share price is 215% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

Orgenesis has higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A

NKGen Biotech has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
NKGen Biotech	N/A	N/A	-479.36%

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by company insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

NKGen Biotech beats Orgenesis on 6 of the 10 factors compared between the two stocks.

How does Orgenesis compare to Portage Biotech?

Portage Biotech (NASDAQ:ATON) and Orgenesis (NASDAQ:ORGS) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Portage Biotech has higher earnings, but lower revenue than Orgenesis. Portage Biotech is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	N/A	N/A	-$6.77M	-$8.18	N/A
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A

Portage Biotech has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	N/A	N/A
Orgenesis	-3,827.81%	N/A	-130.18%

13.4% of Portage Biotech shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 1.9% of Orgenesis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Portage Biotech's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
Portage Biotech	Neutral
Orgenesis	Neutral

Portage Biotech has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.15, meaning that its share price is 215% more volatile than the broader market.

Portage Biotech currently has a consensus price target of $2.00, indicating a potential upside of 502.41%. Given Portage Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Portage Biotech is more favorable than Orgenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Portage Biotech beats Orgenesis on 7 of the 12 factors compared between the two stocks.

Get Orgenesis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORGS vs. The Competition

Export

Metric	Orgenesis	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.07M	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	-0.03	1.66	28.02	24.70
Price / Sales	3.12	127.11	540.37	99.49
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	-0.06	8.17	10.96	6.46
Net Income	-$55.36M	-$3.71M	$3.57B	$337.01M
7 Day Performance	N/A	2.59%	2.12%	1.69%
1 Month Performance	-19.19%	4.41%	5.25%	3.81%
1 Year Performance	-69.92%	49.43%	33.29%	23.90%

Orgenesis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORGS Orgenesis	N/A	$0.40 flat	N/A	-69.9%	$2.07M	$662K	N/A	150
PMCB Nuvilex	0.8092 of 5 stars	$0.74 -3.8%	N/A	-35.1%	$8.27M	N/A	N/A	4	Gap Up
SYBX Synlogic	N/A	$0.70 flat	N/A	-41.4%	$8.20M	$8K	N/A	80
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
NKGN NKGen Biotech	N/A	$0.06 flat	N/A	-80.0%	$7.84M	N/A	N/A	N/A	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORGS) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orgenesis (ORGS) Competitors